Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
World Journal of Urology|November 6, 2013
Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer: multicenter retrospective study by the Sapporo Medical University Urologic Oncology Consortium (SUOC)Tetsuya Shindo, Naoya Masumori, Hiroshi Kitamura, et al.
Journal of Geriatric Oncology|January 10, 2025
Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: A multicenter retrospective studyTetsuya Shindo, Kohei Hashimoto, Toshiki Kenuka, et al.
Immunological Medicine|July 8, 2020
Fatal fulminant hepatitis induced by combined ipilimumab and nivolumab therapy despite favorable histologic response and confirmed by autopsy in a patient with clear cell renal cell carcinomaTerufumi Kubo, Taro Sugawara, Tomoyo Shinkawa, et al.
Anticancer Research|February 29, 2024
Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based ChemotherapyTetsuya Shindo, Kohei Hashimoto, Atsushi Takahashi, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 3, 2023
Prevention of local symptoms in muscle invasive bladder cancer patients: clinical significance of local radiation therapyManabu Okada, Tetsuya Shindo, Keiko Fujino, et al.
World Journal of Urology|May 9, 2024
Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy eraTetsuya Shindo, Kohei Hashimoto, Keiko Fujino, et al.
Cancer Medicine|September 23, 2020
Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancerKohei Hashimoto, Yasuhide Miyoshi, Tetsuya Shindo, et al.
Cancer Immunology, Immunotherapy : CII|July 8, 2021
Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLRTakashi Kobayashi, Katsuhiro Ito, Takahiro Kojima, et al.
Journal of Geriatric Oncology|July 9, 2021
Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matchingNaotaka Nishiyama, Takashi Kobayashi, Shintaro Narita, et al.
Pageof 7